Insder Trading Filing: Irwin Gordon Sold 3,000 Shares of Heska Corp (NASDAQ:HSKA)

November 29, 2016 - By Vivian Park

Insder Trading Filing: Irwin Gordon Sold 3,000 Shares of Heska Corp (NASDAQ:HSKA)

Irwin Gordon Insider Sell

Yesterday, an insider trading transaction was made. Irwin Gordon, the director and an insider of Heska Corp sold exactly 3,000 shares of Heska Corp, worth roughly $198,331 US Dollars, at $66.1 of a share at the time of the transaction. Irwin Gordon right now owns 0.21% of Heska Corp’s total market cap with ownership of 14,876 shares. 

Heska Corp (NASDAQ:HSKA) Ratings Coverage

Out of 3 analysts covering Heska Corp (NASDAQ:HSKA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Heska Corp has been the topic of 4 analyst reports since August 25, 2015 according to StockzIntelligence Inc. CL King initiated Heska Corp (NASDAQ:HSKA) on Friday, April 1 with “Neutral” rating. The stock has “Buy” rating given by Benchmark on Tuesday, November 29. Gabelli downgraded Heska Corp (NASDAQ:HSKA) on Thursday, August 4 to “Hold” rating. On Tuesday, August 25 the stock rating was upgraded by TheStreet to “Hold”.

Insitutional Activity: The institutional sentiment decreased to 1.36 in Q2 2016. Its down 0.18, from 1.54 in 2016Q1. The ratio turned negative, as 6 funds sold all Heska Corp shares owned while 29 reduced positions. 24 funds bought stakes while 30 increased positions. They now own 4.56 million shares or 4.63% more from 4.36 million shares in 2016Q1.

Landscape Mngmt Limited Company last reported 8,510 shares in the company. Goldman Sachs Grp Incorporated holds 0% of its portfolio in Heska Corp (NASDAQ:HSKA) for 13,307 shares. The United Kingdom-based Legal & General Group Inc Public Limited has invested 0% in Heska Corp (NASDAQ:HSKA). Us Fincl Bank De last reported 56,246 shares in the company. Oxford Asset Mngmt has invested 0.09% of its portfolio in Heska Corp (NASDAQ:HSKA). Blackrock Fund Advisors has 0% invested in the company for 159,181 shares. Fuller Thaler Asset Mgmt owns 1,500 shares or 0% of their US portfolio. Art Advsr Limited Liability Corp last reported 0.02% of its portfolio in the stock. Citigroup accumulated 0% or 1,910 shares. Blackrock Ltd Liability Corp last reported 0% of its portfolio in the stock. Timpani Mngmt Ltd Co accumulated 92,539 shares or 1.46% of the stock. Gamco Invsts Inc Et Al holds 0.01% of its portfolio in Heska Corp (NASDAQ:HSKA) for 50,200 shares. Moreover, Jpmorgan Chase & Comm has 0% invested in Heska Corp (NASDAQ:HSKA) for 50 shares. Northern Tru holds 0% of its portfolio in Heska Corp (NASDAQ:HSKA) for 83,537 shares. Tower Cap Limited Liability Company (Trc) holds 0% of its portfolio in Heska Corp (NASDAQ:HSKA) for 983 shares.

Insider Transactions: Since July 1, 2016, the stock had 0 buys, and 15 selling transactions for $6.68 million net activity. 10,000 Heska Corp (NASDAQ:HSKA) shares with value of $423,666 were sold by Wilson Kevin S.. Another trade for 5,000 shares valued at $262,642 was sold by NAPOLITANO JASON A. Asakowicz Steve had sold 4,698 shares worth $246,864. Another trade for 9,998 shares valued at $601,051 was sold by McGinley Michael J. 5,000 shares with value of $324,258 were sold by Lippincott Rod on Tuesday, November 22. 137 Heska Corp (NASDAQ:HSKA) shares with value of $7,028 were sold by McMahon John.

About 113,084 shares traded hands or 11.16% up from the average. Heska Corp (NASDAQ:HSKA) has risen 132.87% since April 26, 2016 and is uptrending. It has outperformed by 127.61% the S&P500.

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The company has a market cap of $461.86 million. The Firm focuses on the canine and feline companion animal health markets. It has a 54.48 P/E ratio. The Company’s divisions include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.

According to Zacks Investment Research, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products.”

Analysts await Heska Corp (NASDAQ:HSKA) to report earnings on March, 2. They expect $0.37 earnings per share, up 32.14% or $0.09 from last year’s $0.28 per share. HSKA’s profit will be $2.53 million for 45.62 P/E if the $0.37 EPS becomes a reality. After $0.45 actual earnings per share reported by Heska Corp for the previous quarter, Wall Street now forecasts -17.78% negative EPS growth.

HSKA Company Profile

Heska Corporation, incorporated on March 27, 1997, develops, makes, markets, sells and supports veterinary products. The Firm is focused on the canine and feline companion animal health markets. The Firm operates in two divisions, which include Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It sells veterinary diagnostic and other specialty veterinary products. The Company’s offerings include blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>